Procter & Gamble Health Ltd
Fundamental Score
Procter & Gamble Health Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of PGHL across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (36.42%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (47.75%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (26.17%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (785.71x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹906.56 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
2 factors identified
Limited Growth History (0.16% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Financial Statements
Comprehensive financial data for Procter & Gamble Health Ltd
About PGHL
Business Overview
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
Company Details
Key Leadership
Corporate Events
PGHL Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Procter & Gamble Health Ltd (PGHL)?
As of 30 Jan 2026, 01:35 pm IST, Procter & Gamble Health Ltd (PGHL) is currently trading at ₹5303.00. The stock has a market capitalization of ₹9.65K (Cr).
Is PGHL share price Overvalued or Undervalued?
PGHL is currently trading at a P/E ratio of 31.44x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Procter & Gamble Health Ltd share price?
Key factors influencing PGHL's price include its quarterly earnings growth (Sales Growth: 3.67%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Procter & Gamble Health Ltd a good stock for long-term investment?
Procter & Gamble Health Ltd shows a 5-year Profit Growth of 8.11% and an ROE of 36.42%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.01 before investing.
How does Procter & Gamble Health Ltd compare with its industry peers?
Procter & Gamble Health Ltd competes with major peers in the Pharmaceuticals. Investors should compare PGHL's P/E of 31.44x and ROE of 36.42% against the industry averages to determine its competitive standing.
What is the P/E ratio of PGHL and what does it mean?
PGHL has a P/E ratio of 31.44x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹31 for every ₹1 of annual earnings.
How is PGHL performing according to Bull Run's analysis?
PGHL has a Bull Run fundamental score of 50/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does PGHL belong to?
PGHL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Procter & Gamble Health Ltd.
What is Return on Equity (ROE) and why is it important for PGHL?
PGHL has an ROE of 36.42%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Procter & Gamble Health Ltd generates profits from shareholders' equity.
How is PGHL's debt-to-equity ratio and what does it indicate?
PGHL has a debt-to-equity ratio of 0.01, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is PGHL's dividend yield and is it a good dividend stock?
PGHL offers a dividend yield of 2.15%, which means you receive ₹2.15 annual dividend for every ₹100 invested.
How has PGHL grown over the past 5 years?
PGHL has achieved 5-year growth rates of: Sales Growth 0.16%, Profit Growth 8.11%, and EPS Growth 8.11%.
What is the promoter holding in PGHL and why does it matter?
Promoters hold 51.82% of PGHL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is PGHL's market capitalization category?
PGHL has a market capitalization of ₹9646 crores, placing it in the Mid-cap category.
How volatile is PGHL stock?
PGHL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for PGHL?
PGHL has a 52-week high of ₹N/A and low of ₹N/A.
What is PGHL's operating profit margin trend?
PGHL has a 5-year average Operating Profit Margin (OPM) of 26.17%, indicating the company's operational efficiency.
How is PGHL's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 3.67% and YoY Profit Growth of 7.54%.
What is the institutional holding pattern in PGHL?
PGHL has FII holding of 7.24% and DII holding of 13.90%. Significant institutional holding often suggests professional confidence in the stock.